Identification

Summary

Sacrosidase is an enzyme replacement therapy used for the treatment of congenital sucrase-isomaltase deficiency (CSID).

Brand Names
Sucraid
Generic Name
Sacrosidase
DrugBank Accession Number
DB06760
Background

Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet; therefore, sacrosidase offers a potential alternative for symptom relief.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Sacrosidase

Pharmacology

Indication

For the treatment of congenital sucrose-isomaltase deficiency (CSID).

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Sacrosidase is a [beta]-fructofuranoside fructohydrolase that hydrolyzes sucrose. Unlike human intestinal sucrase-isomaltase, it has no activity with oligosaccharides containing 1,6 glucosyl bonds.

Absorption

It has been suggested that sucrose is better absorbed (and sacrosidase activity preserved) when patients were given milk before sacrosidase rather than consuming the enzyme product alone. Therefore, it has been recommended to take half dose of sacrosidase just after a protein-containing meal, and the other half of the dose approximately half-way through the meal.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Sucraid
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
SucraidSolution8500 [iU]/1mLOralQOL Medical, LLC1998-04-09Not applicableUS flag
SucraidSolution, concentrate8500 [iU]/1OralQOL Medical, LLC2006-06-162006-06-16US flag

Categories

ATC Codes
A16AB06 — Sacrosidase
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
8A7F670F2Y
CAS number
85897-35-4

References

General References
  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J: Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999 Feb;28(2):137-42. [Article]
KEGG Drug
D05782
PubChem Substance
347910368
RxNav
214817
ChEMBL
CHEMBL1201487
Drugs.com
Drugs.com Drug Page
Wikipedia
Sacrosidase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4WithdrawnTreatmentCongenital Sucrase-isomaltase Deficiency (CSID)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral8500 [iU]/1mL
Solution, concentrateOral8500 [iU]/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US9469847No2016-10-182034-02-07US flag
US9849161No2017-12-262034-02-07US flag
US9255261No2016-02-092034-02-07US flag

Properties

State
Solid
Experimental Properties
Not Available

Drug created at September 14, 2010 16:21 / Updated at February 21, 2021 18:52